Welcome to our dedicated page for Fresh Tracks Therapeutics news (Ticker: FRTX), a resource for investors and traders seeking the latest updates and insights on Fresh Tracks Therapeutics stock.
Fresh Tracks Therapeutics, Inc. (FRTX) has undergone a significant transition from a clinical-stage pharmaceutical company focused on skin diseases to an entity in formal dissolution. The news flow around FRTX documents this shift in detail, from its delisting from The Nasdaq Capital Market to its move to the OTC Pink market and, ultimately, to the termination of trading in connection with its dissolution.
Earlier company descriptions characterized Fresh Tracks, previously referred to as Brickell Biotech, Inc., as a developer of innovative and differentiated therapeutics for dermatology indications. More recent press releases, however, center on corporate actions rather than drug development, including special meetings of stockholders to consider a plan of liquidation and dissolution, adjournments of those meetings, and the company’s intention to seek judicial dissolution if stockholder approval could not be obtained.
News items in 2024 and 2025 focus on legal and procedural milestones: a petition in the Delaware Court of Chancery seeking appointment of a custodian to dissolve the company and wind up its affairs; the court’s scheduling orders; and the eventual consent judgment appointing a custodian under Delaware law. Subsequent announcements describe the planned filing of a Certificate of Dissolution, the authorization of an initial cash distribution to stockholders and certain warrant holders, and the expected cessation of trading on the OTC Pink Market.
This FRTX news page serves as an archive of these developments, allowing investors and researchers to follow the sequence of events that led from Nasdaq suspension and OTC Pink quotation to formal dissolution, cash distributions, and the long-term wind-down process overseen by a court‑appointed custodian.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Fresh Tracks Therapeutics reported positive topline results from the Phase 1 study of FRTX-02, a potential first-in-class oral treatment for atopic dermatitis and autoimmune diseases. The company raised $6.6 million through an at-the-market program in March 2023, enhancing liquidity. For 2022, revenue increased to $6.9 million from $0.4 million in 2021, driven by contract revenue from an asset sale agreement with Botanix. R&D expenses decreased significantly to $14.0 million from $28.2 million, supporting a path toward strategic options aimed at maximizing shareholder value. The net loss shrank to $21.1 million in 2022 from $39.5 million in 2021.
Fresh Tracks Therapeutics announced positive topline results from its Phase 1 clinical trial for FRTX-02, a potential first-in-class treatment for autoimmune diseases. The trial demonstrated that FRTX-02 was generally safe and well-tolerated, supporting its potential as a once-daily oral therapy. Key findings included dose-proportional pharmacokinetics and significant reductions in disease-relevant cytokines, indicating its efficacy in modulating immune responses. The company plans to explore strategic options to enhance shareholder value while advancing development of its innovative therapeutic pipeline.
Fresh Tracks Therapeutics has appointed Andrew Sklawer as the new CEO, effective February 1, 2023, succeeding Rob Brown, who is retiring after leading the company since 2019. Sklawer, a co-founder, will continue to advance the company’s innovative therapeutics targeting autoimmune and inflammatory diseases, with key milestones expected from the ongoing FRTX-02 clinical study.
Brown will remain on the Board of Directors and serve as a special advisor. Reginald Hardy, Chairman, emphasized Sklawer's instrumental role in shaping the company's strategic direction and enhancing shareholder value.